William A Marinelli, MD | |
701 Park Ave, S-1, Minneapolis, MN 55415-1623 | |
(612) 873-9700 | |
(612) 904-4675 |
Full Name | William A Marinelli |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 701 Park Ave, Minneapolis, Minnesota |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1043251671 | NPI | - | NPPES |
717888300 | Medicaid | MN |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RP1001X | Internal Medicine - Pulmonary Disease | 28762 (Minnesota) | Primary |
Mailing Address | Practice Location Address |
---|---|
William A Marinelli, MD 701 Park Ave, Minneapolis, MN 55415-1623 Ph: () - | William A Marinelli, MD 701 Park Ave, S-1, Minneapolis, MN 55415-1623 Ph: (612) 873-9700 |
News Archive
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that it has achieved the target enrollment of the minimum of 100 evaluable relapsed or refractory peripheral T-cell lymphoma (PTCL) patients in the BELIEF registration trial.
Patients with normal left ventricular function who undergo elective unprotected left main coronary artery (ULMCA) percutaneous coronary intervention (PCI) with drug-eluting stents (DES) had favorable outcomes according to new research.
A signaling pathway controlled by transforming growth factor beta (TGF-beta) could be involved in the progression of age-related macular degeneration.
Thousands of patients with an advanced form of lung cancer that carries a specific dysfunctional gene are likely to fare better if treated with a targeted therapy than with traditional chemotherapy, report Dana-Farber Cancer Institute researchers and a team of international collaborators.
EKOS Corporation today announced the launch of two more landmark clinical studies named SEATTLE I & II, intended to further establish the safety and efficacy of its unique, ultrasound-accelerated thrombolysis in treating patients with life-threatening pulmonary embolism.
› Verified 6 days ago
Pascal Frino, M.D Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1 Veterans Dr, Minneapolis, MN 55417 Phone: 612-467-3183 | |
Dr. Ronald Alexander Reilkoff, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 909 Fulton St Se, Minneapolis, MN 55455 Phone: 612-672-7422 | |
Eugenia Shmidt, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 909 Fulton St Se, Minneapolis, MN 55455 Phone: 507-284-2511 | |
Daniel Tesfaye Kebed, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2450 Riverside Ave, Minneapolis, MN 55454 Phone: 612-672-6000 Fax: 612-273-4098 | |
Tenzin Yangchen, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2925 Chicago Ave, Minneapolis, MN 55407 Phone: 612-863-4000 Fax: 763-236-3026 | |
Shelley M Lennox, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 920 E 28th St, Suite 700, Minneapolis, MN 55407 Phone: 612-863-9062 Fax: 612-863-9252 | |
Dr. Markus Meyer, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2450 Riverside Ave, Minneapolis, MN 55454 Phone: 612-672-6000 |